The fact that haploinsufficiency of the Igf1r gene can correct the synaptic deficits of p44+/+ single-transgenics prompted us to test whether IGF-1R is a valid pharmacologic target for the prevention/treatment of the synaptic deficits that occur in patients with AD. The gene discussed is IGF1R; the disease is Alzheimer disease.